Evidence map›Paper›PMID 26861919›Full record

ArticleVirchows Archiv : an international journal of pathology2016

In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading.

C G Picanço-Albuquerque, C L Morais, F L F Carvalho, S B Peskoe, J L Hicks, O Ludkovski, T Vidotto, H Fedor, E Humphreys, M Han and 5 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Detection and Correlation of Single and ConcomitantInternational journal of molecular sciences · 2019
    Article
  11. Article
  12. The combination of PTEN deletion and 16p13.3 gain in prostate cancer provides additional prognostic information in patients treated with radical prostatectomy.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019
    Article
  13. Molecular Biomarkers in the Clinical Management of Prostate Cancer.Cold Spring Harbor perspectives in medicine · 2018
    Review
  14. Article
  15. Use of multicolor fluorescence in situ hybridization to detect deletions in clinical tissue sections.Laboratory investigation; a journal of technical methods and pathology · 2018
    Review
  16. Review
  17. Distinct subtypes of genomicMolecular cytogenetics · 2018
    Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

C G Picanço-AlbuquerqueDepartment of Genetics, Ribeirão Preto Medical School, University of Sao Paulo, Ribeirão Preto, Brazil.
C L MoraisDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
F L F CarvalhoDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
S B PeskoeDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
J L HicksDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
O LudkovskiDepartment of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada.
T VidottoDepartment of Genetics, Ribeirão Preto Medical School, University of Sao Paulo, Ribeirão Preto, Brazil.
H FedorDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
E HumphreysDepartment of Urology and the James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
M HanDepartment of Urology and the James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
E A PlatzDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
A M De MarzoDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
D M BermanDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
T L LotanDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
J A SquireDepartment of Genetics, Ribeirão Preto Medical School, University of Sao Paulo, Ribeirão Preto, Brazil. jsquireinsp@gmail.com.
Johns Hopkins University · USJohns Hopkins Medicine · USQueen's University · CAUniversidade de São Paulo · BR

Funding

TRANSGENIC MODELS FOR PROSTATE CANCER AND AUTOIMMUNITYP50CA058236 · NCI · JOHNS HOPKINS UNIVERSITY · PI DENMEADE, SAMUEL R · 1992 to 2020
$43.9M
6 · The paper itself

Abstract

The prognostic value of phosphatase and tensin homolog (PTEN) loss in prostate cancer has primarily been evaluated by either fluorescence in situ hybridization (FISH) or immunohistochemistry (IHC). Previously, we found that PTEN loss by IHC was associated with increased risk of upgrading from biopsy (Gleason 3 + 3) to prostatectomy (Gleason 7+). Now, using an evaluable subset of 111 patients with adjacent biopsy sections, we analyzed the association between PTEN deletion in cancer and the odds of upgrading by a highly sensitive and specific four-color FISH assay. We also compared the concordance of PTEN loss by IHC and PTEN deletion by FISH. PTEN deletion was found in 27 % (12/45) of upgraded cases compared with 11 % (7/66) of controls (P = 0.03). Cancers with PTEN deletions were more likely to be upgraded than those without deletions (adjusting for age odds ratio = 3.40, 95 % confidence interval 1.14-10.11). With respect to concordance, of 93 biopsies with PTEN protein detected by IHC, 89 (96 %) had no PTEN deletion by FISH, and of 18 biopsies without PTEN protein by IHC, 15 had homozygous or hemizygous PTEN deletion by FISH. Only 4 biopsies of the 93 (4 %) with PTEN protein intact had PTEN deletion by FISH. When the regions of uncertainty in these biopsies were systematically studied by FISH, intra-tumoral variation of PTEN deletion was found, which could account for variation in immunoreactivity. Thus, FISH provides a different approach to determining PTEN loss when IHC is uncertain. Both FISH and IHC are concordant, showing consistent positive associations between PTEN loss and upgrading.

Indexed as

In Situ Hybridization, FluorescenceAgedBiomarkers, TumorBiopsy, NeedleHumansImmunohistochemistryMaleMiddle AgedProstatectomyProstatic NeoplasmsPTEN PhosphohydrolaseBiomarkers, TumorPTEN PhosphohydrolasePTEN protein, humanGleason upgradeHemizygous and homozygous genomic deletionPrognostic biomarker assayTumor suppressor gene

Identifiers

PMID26861919
OpenAlexW2260123348

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.